• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Reflections on 2024’s Progress in R/R CLL

Opinion
Video

Panelists discuss how the relapsed/refractory chronic lymphocytic leukemia treatment landscape evolved significantly in 2024 with expanded Bruton tyrosine kinase inhibitor options, growing real-world evidence for newer agents, and emerging combination strategies, while expressing optimism for future advances in personalized therapy approaches and novel drug development.

Related Videos
Dr Arielle Kauvar
Dr Brian Koffman
1 expert in this video
1 expert in this video
Paula Rodríguez-Otero, MD, PhD
5 Experts are featured in this series.
5 experts are featured in this series.
5 experts in this video
5 experts in this video
Dr Brian Koffman
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.